Compare Nuscale Power Corporation (SMR) vs Tempus AI (TEM) Price & Performance

NuScale Power (SMR) trades at $7.67, down 4.42% today, reflecting ongoing investor concerns about the company's financial performance. The stock shows bearish technical signals with negative moving averages and oscillators, while fundamentally the company faces significant challenges with a net income margin of -3,888.7% and negative cash flow from operations of $459.61 million in 2025. Recent news highlights both the nuclear industry's growth potential and specific challenges facing NuScale, including ongoing legal investigations.

Despite analyst consensus pointing to potential upside with a $11.25 price target, SMR faces substantial execution risks as it burns cash while pursuing commercialization. The company's ability to secure additional financing and achieve revenue growth will be critical for survival, making this a high-risk investment suitable only for investors comfortable with speculative nuclear technology plays.

Tempus AI (TEM) trades at $70.29, down 2.35% on the day, with a bullish technical signal despite recent weakness. The company reported Q2 2026 revenue growth of 22% year-over-year and beat EPS estimates for three consecutive quarters, though it remains unprofitable with a net income margin of -17.77%. Recent positive developments include FDA clearance for its ECG-MR AI product and expanded data licensing agreements, fueling investor optimism in the healthtech sector.

The investment outlook is cautiously optimistic, driven by strong analyst support (64% buy ratings) and a consensus price target of $72.60, implying modest upside. Key opportunities include accelerating adoption of AI-powered diagnostics and strategic acquisitions, but risks persist from persistent cash burn, insider selling, and intense competition in the precision medicine space.